Syngene International Ipo

Some of the companies that are trading above their issue price include Navkar Corporation, Syngene International, PNC Infratech and VRL Logistics.

Syngene International's IPO was subscribed over 32 times last month, helping it raise an estimated Rs 550 crore. The company had also raised Rs 150 crore from anchor investors. The IPO had opened on July 27 and closed on July 29.

The move follows the blockbuster IPO of Syngene International, biotechnology major Biocon's research arm. With this public offer, the company is expected to be valued at around Rs 15,000 crore.

In a strong show, the Rs 550-crore initial public offer (IPO) of biotechnology major Biocon's research arm, Syngene International, was over-subscribed 32.03 times on its last day on Wednesday as both retail and institutional investors bid aggressively for the shares.

Syngene International's initial public offer (IPO) was over-subscribed on its second day on Tuesday.

The IPO received bids for 51.66 lakh shares against 1.6 crore on offer, according to NSE data till 1600 hours.

Syngene International is offering 2.2 crore shares in the price band of Rs 240-Rs 250. The issue is essentially an offer for sale wherein proceeds from the IPO will not be ploughed back in the company. Its parent Biocon is selling 11 per cent stake in the company which will bring down its stake to 74.5 per cent from 85.5 per cent now.

Syngene's initial public offer (IPO) will open on July 27.

Biocon said the biopharmaceuticals segment benefitted from a strong contribution from the insulin and biosimilar business in the emerging markets.

Syngene provides contract drug discovery, research and manufacturing services to 17 of the world's top 20 pharmaceutical companies, including Bristol Myers Squibb & Co and Abbott Laboratories Ltd. Its revenue rose 25 percent in the last three years.

The company filed for the draft red herring prospectus with Sebi. It plans to raise Rs 600 crore by selling 24 million equity shares.

Biocon last year sold a 10 percent stake in Syngene to private equity fund Silver Leaf Oak, valuing Syngene at Rs 3800 crore.

Some of the companies that are trading above their issue price include Navkar Corporation, Syngene International, PNC Infratech and VRL Logistics.

Syngene International's IPO was subscribed over 32 times last month, helping it raise an estimated Rs 550 crore. The company had also raised Rs 150 crore from anchor investors. The IPO had opened on July 27 and closed on July 29.

The move follows the blockbuster IPO of Syngene International, biotechnology major Biocon's research arm. With this public offer, the company is expected to be valued at around Rs 15,000 crore.

In a strong show, the Rs 550-crore initial public offer (IPO) of biotechnology major Biocon's research arm, Syngene International, was over-subscribed 32.03 times on its last day on Wednesday as both retail and institutional investors bid aggressively for the shares.

Syngene International's initial public offer (IPO) was over-subscribed on its second day on Tuesday.

The IPO received bids for 51.66 lakh shares against 1.6 crore on offer, according to NSE data till 1600 hours.

Syngene International is offering 2.2 crore shares in the price band of Rs 240-Rs 250. The issue is essentially an offer for sale wherein proceeds from the IPO will not be ploughed back in the company. Its parent Biocon is selling 11 per cent stake in the company which will bring down its stake to 74.5 per cent from 85.5 per cent now.

Syngene's initial public offer (IPO) will open on July 27.

Biocon said the biopharmaceuticals segment benefitted from a strong contribution from the insulin and biosimilar business in the emerging markets.

Syngene provides contract drug discovery, research and manufacturing services to 17 of the world's top 20 pharmaceutical companies, including Bristol Myers Squibb & Co and Abbott Laboratories Ltd. Its revenue rose 25 percent in the last three years.

The company filed for the draft red herring prospectus with Sebi. It plans to raise Rs 600 crore by selling 24 million equity shares.

Biocon last year sold a 10 percent stake in Syngene to private equity fund Silver Leaf Oak, valuing Syngene at Rs 3800 crore.